Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18429067 | 0.83 | MEN1 (0.55) | — | |
| SCHEMBL18469972 | 0.82 | CHRM1 (0.57) | CHRM2CHRM3OPRD1OPRM1OPRK1 | |
| SCHEMBL5725403 | 0.81 | ALDH1A1 (0.43) | CHRM2CHRM3OPRD1OPRM1OPRK1 | |
| SCHEMBL22797844 | 0.79 | HRH3 (0.40) | CHRM2OPRM1CCR5KCNH2 | |
| SCHEMBL5801159 | 0.78 | KDM4E (0.47) | OPRM1OPRK1ADRA1AKCNH2DRD2 | |
| SCHEMBL5969496 | 0.77 | CCR5 (0.53) | CHRM2OPRD1OPRM1SIGMAR1ADRA1A | |
| SCHEMBL18428936 | 0.76 | OPRM1 (0.44) | CHRM3OPRD1OPRM1OPRK1SIGMAR1 | |
| SCHEMBL2896994 | 0.75 | L3MBTL3 (0.46) | CHRM2CHRM3OPRD1OPRM1OPRK1 | |
| SCHEMBL18475969 | 0.75 | NOS2 (0.47) | OPRM1OPRK1SIGMAR1ADRA1AKCNH2 | |
| SCHEMBL5969537 | 0.75 | CCR5 (0.49) | OPRM1SIGMAR1CCR5KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822262-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| CN-107949558-B | Muscarinic agonists | 赫普泰雅治疗有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-11091456-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| EP-3822262-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2021-05-19 | — | — | EP | disclosed |
| EP-3331869-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-20190270718-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10351545-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-07-16 | — | — | US | disclosed |
| US-10167272-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| EP-3331869-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| US-20180155315-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-20180022726-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9758506-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170037025-A1 | Muscarinic Agonists | NXERA PHARMA UK LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| WO-2017021730-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091456-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM3 3/4885OPRD1 183/4885 |
| US-20180022726-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM3 3/4885OPRD1 183/4885 |
| US-20190270718-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM3 3/4885OPRD1 183/4885 |
| US-10351545-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM3 3/4885OPRD1 183/4885 |
| US-20170037025-A1 | Muscarinic Agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM3 3/4885OPRD1 183/4885 |
| US-20180155315-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM3 3/4885OPRD1 183/4885 |
| US-10167272-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM3 3/4885OPRD1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.